Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SMARCB1-Deficient Malignant Orbital Neoplasm with Features Overlapping Myxoid Epithelioid Sarcoma: A Diagnostic Challenge.

Head and neck pathology·2026
Same author

Anaplastic meningioma with abundant extracranial metastases: a case report.

Journal of medical case reports·2026
Same author

In Silico Regression Modeling and Improved Interpretability To Predict the Transport Inhibitory Activity of Breast Cancer Resistance Protein.

ACS omega·2026
Same author

Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion.

Cancer medicine·2026
Same author

Efficacy of venetoclax combined with azacitidine for advanced blastic plasmacytoid dendritic cell neoplasm: experience from two Japanese cases.

Journal of clinical and experimental hematopathology : JCEH·2026
Same author

The International Classification of Diseases for Oncology, 4th Edition (ICD-O-4): An overview.

Cancer epidemiology·2026
Same journal

[Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in management of systemic AL amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Treatment strategies for relapsed or refractory multiple myeloma: proposals for optimal treatment sequencing].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Treatment strategies for newly diagnosed multiple myeloma and the clinical significance of minimal residual disease negativity].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent topics in smoldering multiple myeloma: early intervention or active monitoring?]

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Balancing hemostasis and thrombosis in aging people with hemophilia].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

[Waldenström's macroglobulinemia].

Reiko Watanabe1

  • 1Division of Hematology, Saitama Medical Center, Saitama Medical University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 14, 2015
PubMed
Summary
This summary is machine-generated.

Waldenström macroglobulinemia (WM) is a rare B-cell cancer. New genomic discoveries like MYD88 and CXCR4 mutations are changing how we diagnose and treat this incurable disease.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.6K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

32.6K

Related Experiment Videos

Last Updated: Apr 1, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.6K
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

32.6K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Context:

  • Waldenström macroglobulinemia (WM) is a rare, incurable B-cell neoplasm.
  • Characterized by bone marrow infiltration and monoclonal immunoglobulin M production.
  • Treatment strategies are individualized based on patient and disease factors.

Purpose:

  • To review current therapeutic strategies for WM.
  • To highlight recent genomic discoveries in WM.
  • To discuss the potential impact of these mutations on diagnosis and treatment.

Summary:

  • Current WM treatments often involve rituximab, with improved outcomes reported for combinations including bendamustine, bortezomib, or carfilzomib.
  • For older patients, oral fludarabine shows superiority over chlorambucil.
  • Bruton tyrosine kinase (BTK) inhibitors like ibrutinib are promising.
  • Whole-genome sequencing identified MYD88L265P (in ~90% of patients) and CXCR4WHIM mutations.
  • MYD88L265P influences WM cell proliferation and survival via IRAK/BTK/NFκB pathways.
  • CXCR4WHIM is linked to tumor progression and ibrutinib resistance.

Impact:

  • Understanding the genomic landscape of WM is crucial for developing targeted therapies.
  • These mutations may significantly alter the diagnostic and prognostic approaches to WM.
  • Future treatments may be tailored based on the presence of MYD88 and CXCR4 mutations.